Background {#sec1-1}
==========

Fatigue is a complex and common symptom present in a wide range of neurological conditions including multiple sclerosis (MS). In fact, it is reported to be one of the three most frequent disabling symptoms in MS with as many as 90% of patients reporting fatigue.\[[@ref1][@ref2][@ref3][@ref4]\] It often severely interferes with patient\'s work, family, and social life. Clinically, patients with MS report fatigue as exhaustion, lack of energy, increased somnolence or worsening of symptoms and weakness exacerbated by activity and heat (Uthoff phenomenon).\[[@ref3]\]

Certain factors such as neurological impairment, spasticity, motor weakness, nocturia, pain, depression, sleep disturbances, and heat sensitivity correlate consistently with fatigue and considered secondary causes of fatigue in MS.\[[@ref1][@ref2]\]

Quality-of-life (QoL) is defined as individual perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals expectations, standards and concerns. Several studies have reported that QoL is worse in patients with MS as compared to healthy controls with a higher prevalence of depression and fatigue.\[[@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14]\]

Although there is a plethora of literature regarding the effect of MS related fatigue on the QoL in the western countries, but no case series has been published with Indian population of patients with MS as per our knowledge. The objective of this prospective study was to observe the prevalence of fatigue in Indian patients with MS and also to see its effect on various domains of QoL.

Patients and Methods {#sec1-2}
====================

This prospective observational study was performed with 31 patients with MS (25 females), who visited the out-patient facility or admitted in the Department of Neurology of the University Tertiary Research Hospital between February 2010 and December 2011. Internal ethics committee approval was taken for the study. Informed consent was taken from all patients for participation. Patients with definite MS according to the McDonald\'s (2005),\[[@ref15]\] criteria were included in the study irrespective of age and gender. Patients were excluded from the study if they had an acute relapse in the preceding 2 months, having systemic infection, received pulse methylprednisolone during the past 4 weeks and already receiving medication to reduce fatigue.

All patients who agreed to participate in the study were evaluated with a questionnaire, which included personal data, Kurtzke\'s expanded disability status scale (EDSS),\[[@ref16]\] and Krupp\'s fatigue severity scale (FSS).\[[@ref17]\] History of medication use such as antidepressants, sedatives and anti-hypertensives, which may have contributed to fatigue, was recorded. The QoL was assessed using World Health Organization (WHO) QOL-BREF questionnaire.\[[@ref18]\] Patient related information such as filling of proformas, history, and clinical examination of patients was carried out by a Neurologist.

Investigations {#sec2-1}
--------------

Patients underwent a complete hemogram and peripheral smear, random blood sugar, renal and liver function tests, thyroid function tests apart from imaging when necessary. Other medical conditions causing fatigue were ruled out when clinically indicated.

Evaluation of disease severity {#sec2-2}
------------------------------

Disease severity in patients was evaluated using the Kurtzke\'s EDSS.\[[@ref16][@ref19]\] The scale provides a score between 0 (very little disability with a normal neurological examination) to a maximum of 10 (death due to MS). The first levels 1-4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5-9.5 refer to the loss of ambulatory ability. In addition, it also provides eight subscale measurements called functional system (FS) scores. These systems include pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral, and others. The FS are scored on a scale of 0 (low level of problems) to 5 (high level of problems) to reflect the level of disability observed clinically. The gait and FS scores determine the total EDSS scores.

Evaluation of fatigue {#sec2-3}
---------------------

Fatigue severity was assessed using Krupp FSS, which consists of nine items each rated on a seven point scale, which has five equidistant anchor points: Strongly disagree (1), rare (2,3), sometimes (4), frequently (5,6), and strongly agree (7). The score is obtained by computing the average of the nine items with higher scores indicating increasing fatigue severity. Patients having a total FSS score of 36 and above were categorized as having fatigue and those who have a score \<36 were categorized as not having fatigue.\[[@ref17]\]

Evaluation of QoL {#sec2-4}
-----------------

The QoL of patients was assessed using the WHO QOL-BREF questionnaire. This contains a total of 26 questions, which measure the QoL in four domains: Physical health, psychological, environmental, and social relationships. The mean score of items within each domain is used to calculate the domain score. These raw scores are then converted to the final transformed scores on a 0-100 scale.\[[@ref18]\]

Statistical analysis {#sec2-5}
--------------------

Statistical analysis was performed using the SPSS 15.0 software. Descriptive statistics included frequency, means, and standard deviation for quantitative variables such as age, age at first symptoms, number of episodes, EDSS and FSS scores and duration of illness. All quantitative measures were treated with parametric statistical analysis such as Student\'s t-test like; FSS, WHO QoL domain scores in patients with MS with and without fatigue. Qualitative measures such as correlation between FSS scores and various domains of WHO QoL were analyzed using Chi-square test.

Results {#sec1-3}
=======

Study included 31 patients and their clinical and demographic data given in [Table 1](#T1){ref-type="table"}.

###### 

Clinical and demographic data of the patients

![](JNRP-4-278-g001)

Their clinical presentation has been given in the [Table 2](#T2){ref-type="table"}.

###### 

Clinical symptoms in multiple sclerosis
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Profile of fatigue in patients with MS {#sec2-6}
--------------------------------------

The mean fatigue score was 38.7 ± 18.5, which is above the cut off value of 36 in the FSS. The prevalence of fatigue in patients with MS was 58.1% (18/31).

Comparison of parameters between patients of MS with and without fatigue {#sec2-7}
------------------------------------------------------------------------

The mean age and age at 1^st^ symptom was significantly greater in the group of MS patients with fatigue as compared to those without fatigue (*P* = 0.01 and 0.001 respectively) \[[Table 3](#T3){ref-type="table"}\].

###### 

Comparison of parameters between patients of MS with and without fatigue
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QoL {#sec2-8}
---

All four domains of QoL; physical health, psychological, environmental, and social relationships were significantly more impaired in the group of patients with fatigue than in those without fatigue as mentioned in [Table 4](#T4){ref-type="table"}.

###### 

Comparison between patients of MS with and without fatigue -- quality of life
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Discussion {#sec1-4}
==========

Fatigue is a common symptom in a wide range of clinical conditions. It is one of the key factors that affect the QoL in general. Many factors such as sleep, depression, and disability contribute to fatigue.\[[@ref5]\] Very few studies in India have been conducted in patients with MS and these aspects have not been addressed by most of the authors. The aim of this study was to estimate the prevalence of fatigue in patients with MS and its effect on QoL of these patients.

In our study, patients of MS with and without fatigue were compared and it was found that the severity of fatigue correlated with poorer QoL in all domains. The observation highlights the importance of initiating management of fatigue in these patients as it will help not only in improving the symptom, but also will provide a global higher QoL.

Fatigue prevalence was high (58.1%) in our study. Even higher prevalence has been reported in the previous studies with much greater sample size like North American Research Committee on Multiple Sclerosis survey.\[[@ref4]\] This survey observed that MS patients with fatigue tended to be older and had more disability according to Patient Determined Disease Scale (PDDS) as compare MS patients without fatigue. However, duration of illness tended to be comparable in the two groups. Respondents with severe fatigue also had significantly higher mobility impairment as measured by PDDS scores compared with respondents with mild/moderate fatigue. Similar significant correlation between fatigue and mobility impairment was reported in another study by Schwartz *et al*.\[[@ref20]\] However, Krupp *et al*.,\[[@ref3]\] found insignificant correlation between EDSS and fatigue scores.

Attempts have been made to identify factors contributing to fatigue in MS. Corpus callosal atrophy,\[[@ref21]\] cortical atrophy of the parietal lobe with dysfunctions in higher-order aspects of motor control,\[[@ref22]\] regional atrophy of supratentorial brain parenchyma involving the cerebral cortex, nearby white matter and the caudate head areas,\[[@ref23]\] significant white matter atrophy in the posterior part of the corpus callosum and significant grey matter atrophy of the left superior frontal sulcus, left pre-central gyrus, posterior cingulate cortex, right thalamus, and left middle frontal gyrus have been some of the structural derangement in the brain found to be correlating with fatigue in MS.\[[@ref24][@ref25]\]

The causes of primary fatigue in MS include down regulation of gamma-aminobutyric acid activity as a compensatory mechanism due to conduction failure in demyelinated pyramidal tract fibers.\[[@ref26][@ref27]\] Conduction block,\[[@ref28][@ref29]\] and activity dependent conduction block are also considered to be the mechanisms responsible for fatigue in MS patients.\[[@ref30]\] Cytokine mechanism with increased level of tumor necrosis factor-α levels and interferon-γ levels are found in fatigued MS patients compared to non-fatigued patients and considered to be responsible for fatigue.\[[@ref31]\]

These tests were not done or reported in the present study.

In a previous longitudinal study with MS patients, authors examined the symptom cluster of fatigue, pain, and depression as a correlate of reduced QoL. Cluster analysis revealed the presence of three subgroups differing in experiences of the three symptoms. The sub-group with the lowest scores on all three symptoms had the highest QoL, whereas the sub-group with the highest scores on the symptoms had the worst QoL. This observation supports the concept of fatigue, pain and depression as a symptom cluster, which correlates with reduced QoL in patients with MS.\[[@ref32]\] Another case-control study in women with relapsing-remitting multiple sclerosis (RRMS) found that pain and pain intensity were significantly more in the RRMS group as compared to controls. However, fatigue and depression intensity was not significantly different between the groups. It was observed that increased fatigue intensity was a predictor for decreased physical QoL in all women, regardless of group.\[[@ref33]\]

Ghaem and Borhani Haghighi (2008) in their study found 87.2% of patients with MS had poor sleep. Significant high positive correlation was observed between the quality of mental and physical health composite scores. There was a significant negative correlation between the quality of physical score and age, fatigue score, EDSS score and Pittsburgh Sleep Quality Index (PSQI). Linear regression analysis showed that PSQI score, EDSS, and fatigue score were predictors in the model between the quality of physical score and covariates. Linear regression model showed that fatigue score and PSQI were predictors in the model between the quality of mental score and covariates.\[[@ref34]\]

The explanation could be that the three symptoms are often co-occurring and possibly synergistic in persons with MS and are etiologically linked through cytokine induced manifestations of sickness behavior with diffuse axonal damage across different regions of the central nervous system.\[[@ref31][@ref35][@ref36]\] Researchers have identified fatigue, depression, and pain as a symptom cluster, which is associated with reduced physical activity and QoL in persons with MS.\[[@ref37][@ref38]\] Another study reported decreased QoL in all domains with physical functioning being the most affected in patients with MS.\[[@ref19]\] The results of this study corroborate the notion that fatigue, increased lower limb tone, poor gait, and greater disability are independent factors that negatively affect the QoL especially physical functioning domain in patients with MS. Fatigue negatively affects both the physical and the mental components of the QoL irrespective of the duration of the disease or the degree of disability.

Conclusions {#sec1-5}
===========

The prevalence of fatigue was found to be high in patients with MS in the present study. All four domains of QoL; physical health, psychological, environmental, and social relationships were significantly more impaired in the group of patients with fatigue than in those without fatigue. The treatment of fatigue therefore will not only help alleviating fatigue, but also improve QoL of these patients.

Limitations of the study {#sec2-9}
------------------------

The study had a relatively small sample size. A follow-up study could have not only thrown light on the impact of fatigue on other co-morbidities, but also effectiveness of treatment in improving QoL and functional abilities of these patients.

Future directions {#sec2-10}
-----------------

Fatigue is a symptom with multiple contributory factors such as poor sleep, depression, disability, and autonomic dysfunction. Larger studies will be necessary to find out, which of these abnormalities are the major contributors to fatigue in MS. This may have potential therapeutic implications in the form of early recognition and treatment of these comorbidities. Correlation of fatigue with radiological/imaging abnormalities in these patients can also be attempted.
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